Project Grant K99CA303777
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $129K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This $930,500 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports innovative research by the University of Arizona to understand the fundamental biological mechanisms of cancer development, progression, and potential therapeutic interventions. The research focuses on investigating the role of loss of chromosome Y (LOY) in bladder cancer, examining how LOY in both tumor cells and immune cells can promote cancer growth and induce tumor...
- This Project Grant award, totaling $354,658, was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Johns Hopkins University. The objective is to perform a systematic analysis of P27 alterations in both primary and metastatic prostate cancer, with the ultimate aim of understanding how subclonal P27 loss mediates worse prostate cancer outcomes, particularly in African American males who experience higher mortality rates from the disease. This research...
- The University of Southern California was awarded a $613,220 Project Grant under the National Cancer Institute's Cancer Cause and Prevention Research (CFDA 93.393) program. The grant, which runs from February 1, 2025 to January 31, 2030, will fund research to investigate the contribution of germline copy number variations to the susceptibility of aggressive prostate cancer in men of African and European ancestry. The project aims to leverage existing genome-wide association study, whole-exome...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support research at the Weill Medical College of Cornell University to investigate the role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer. The $683,979 award, effective June 1, 2025 through April 30, 2030, will fund a multi-institutional collaborative effort to define the propensity of prostate cancers harboring SPOP mutations to progress to specific subtypes...
- This Project Grant award, valued at $531,825.00 and funded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports research by The Trustees of Columbia University in the City of New York to uncover the molecular mechanisms underlying castration sensitivity in the prostate epithelium. The research aims to define the intrinsic and extrinsic pathways that mediate castration response and ferroptosis, a form of regulated cell death, in the normal prostate. This work may...
- This federal Project Grant award of $134,757.00, provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program, supports research to identify therapeutic vulnerabilities of chromosome 3 rearranged myeloid leukemias. The overall objective is to develop and apply novel proteogenomic approaches to study these aggressive blood cancers, which currently lack targeted precision therapies and have dismal 5-year survival rates. The award will fund research...
- This $150,104 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand the evolutionary trajectories of complex genomic rearrangements in cancer. The project aims to develop novel computational approaches, "AGAVE" and "ROSE", to characterize the timing and dynamics of focal amplifications and structural variants during tumor evolution. The research will map these evolutionary patterns across...
- The U.S. National Cancer Institute (NCI) awarded a 5-year, $680,433 Project Grant to the University of California, San Francisco (UCSF) under the NCI's Cancer Detection and Diagnosis Research (CFDA 93.394) program. The grant supports research aimed at using cutting-edge spatial proteogenomic technologies and pathology artificial intelligence (PAI) to improve prognostic estimation and elucidate the underlying biology driving PAI outcomes in prostate cancer. The project seeks to: 1) understand the...
- This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...
- This $663,383 Project Grant was awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Georgetown University on August 1, 2025. The project aims to conduct proactive outreach and provide streamlined genetic testing for prostate cancer survivors. This research is crucial to customize cancer treatment and guide prevention, as germline pathogenic variants in DNA-repair genes are common and clinically significant in prostate cancer patients. Despite clear...